The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2006, 08, 4 (pages: 29 - 40)

Injecting Buprenorphine Tablets: A Manageable Risk

Reisinger M.

Summary: Buprenorphine for the treatment of heroin addicts was launched on the French market in February 1996. Ten years on, more than 85,000 patients are undergoing this treatment and most reports are positive. However, it has been observed that a certain proportion of patients are using buprenorphine inappropriately. Instead of taking buprenorphine sublingually, as prescribed, these users crush tablets to inject them3. This practice of injection also involves individuals not undergoing this treatment. The same problem of buprenorphine diversion and injection has been observed in several other countries, like England, Scotland, Ireland, New Zealand, Australia, Finland and the Czech Republic. Given the reported substantial benefits of buprenorphine for individuals and for public health generally, it is important to analyse the problem of buprenorphine injection to get a better understanding of the origins of this problem, its incidence, consequences, causes and remedies.


AU-CNS Associazione per lā€™Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali
Association for the Application of Neuroscientific Knowledge to Social Aims
Via XX Settembre, 83 ā€“ 55045 PIETRASANTA (Lucca) - Italy
P. IVA 01681650469 ā€“ Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page